Skip to main content

Advertisement

Table 2 Mean (S.D.) Platelet Contractile Force, Clot Elastic Modulus and Thrombin Generation Time at Baseline and Following Increasing Enoxaparin Antifactor Xa Activity

From: A hypothesis-generating study to evaluate platelet activity in diabetics with chronic kidney disease

  Group I Group II Group III  
Antifactor Xa Activity Controls (n = 10) Renal Dysfunction (n = 13) Diabetes and Renal Dysfunction (n = 7) P-value
Baseline     
PCF 8.5 (1.4) 9.8 (1.5) 12.0 (2.9)* 0.003
CEM 23.2 (5.4) 29.0 (9.5) 37.3 (15.5)* 0.03
TGT§ 222.0 (60.3) 235.4 (53.2) 270.0 (52.0) NS
0.25 IU/mL     
PCF 7.0 (1.8) 7.5 (1.6) 8.8 (2.9) NS
CEM 21.1 (4.1) 22.6 (4.1) 24.6 (7.1) NS
TGT 273.0 (68.5) 327.7 (70.8) 325.7 (76.3) NS
0.50 IU/mL     
PCF 5.5 (1.9) 5.6 (1.8) 6.3 (2.4) NS
CEM 17.2 (5.1) 19.1 (4.4) 19.4 (5.0) NS
TGT 318.0 (68.1) 440.0 (97.5)* 420.0 (86.6) 0.007
1.0 IU/mL     
PCF 3.6 (1.7) 3.0 (1.7) 4.0 (2.1) NS
CEM 11.9 (4.5) 10.0 (4.6) 12.9 (6.1) NS
TGT 423.0 (128.4) 588.5 (96.0)* 552.9 (114.7) 0.005
3.0 IU/mL     
PCF 1.5 (1.3) 0.6 (0.2) 1.0 (0.9) 0.06
CEM 4.8 (4.4)* 0.8 (0.8) 0.9 (0.8) 0.003
TGT 780.0 (317.5) 1200.0 (0)* 1200.0 (0)* < 0.0001
  1. PCF – Kdynes, CEM – Kdynes/cm2,§TGT – seconds
  2. NS – not significant
  3. * Statistically significant